Risk factors for early visual deterioration in temporal arteritis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 11, 2007, Pages 1255-1259

  Loddenkemper, Tobias ^a,c   Sharma, Pankaj ^d   Katzan, I ^c   Plant, Gordon T ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; CORTICOSTEROID;

ADULT; AGED; ARTICLE; BLOOD VESSEL BIOPSY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; EARLY DIAGNOSIS; EYE SWELLING; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TEMPORAL ARTERITIS; TEMPORAL ARTERY; UNIVARIATE ANALYSIS; VISUAL IMPAIRMENT; BIOPSY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; PAPILLEDEMA; PATHOLOGY; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL DISORDER;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PAPILLEDEMA; RETROSPECTIVE STUDIES; RISK FACTORS; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; VISION DISORDERS; VISUAL ACUITY;

EID: 35748944535     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.113787     Document Type: Article

References (50)

1. Hunder GG, Bloch DA, Michel BA, et al. The American Collegeof Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
2. Kupersmith MJ, Speira R, Langer R, et al. Visual function and quality of life among patients with giant cell (temporal) arteritis. J Neuroophthalmol 2001;21:266-73.
3. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374-8.
4. Mosher HA. Prognosis in temporal arteritis. Arch Ophthalmol 1959;62:641-4.
5. Meadows SP. Temporal arteritis and loss of vision. Trans Ophthal Soc UK 1954;74:13-24.
6. Meadows SP. Temporal or giant cell arteritis. Proc R Soc Med 1966;59:329-33.
7. Healey LA, Wilske KR. Manifestations of giant cell arteritis. Med Clin North Am 1977;60:261-71.
8. Sorensen PS, Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. Acta Med Scand 1977;201:207-13.
9. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis. A 25-year epidemiologic, clinical and pathologic study. Ann Int Med 1978;88:162-7.
10. Calamia RJ, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 1980;6:403.
11. Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. J Rheumatol 1980;7:361-4.
12. Graham E, Holland A, Avery A, et al. Prognosis in giant-cell arteritis. Br Med J 1981;282:269-71.
13. Bengtsson BA. Eye complications in giant cell artertitis. Acta Med Scand 1982;656:S38-43.
14. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47:733-9.
15. Chmelewski WL, McKnight KM, Agudelo CA, et al. Presenting features and outcomes in patients undergoing temporal artery biopsy. Arch Intern Med 1992;152:1690-5.
16. Liu GT, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis. Ophthalmology 1994;101:1779-85.
17. Meli B, Landau K, Gloor BP. The bane of giant cell arteritis from an ophthalmological viewpoint. Schweiz Med Wochenschr 1996;126:1821-8.
18. Font C, Cid MC, Coll-Vincent B, et al. Clinical features in patients with permanent loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997;36:251-4.
19. Bahlas S, Ramus-Remus C, Davis C. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998;25:99-104.
20. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000;79:283-92.
21. Wenkel H. Bilateral amaurosis in 11 patients with giant cell arteritis confirmed by arterial biopsy. Klin Monatsbl Augenheilkd 2001;218:658-61.
22. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001;85:1061-4.
23. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003;217:239-59.
24. Chan CC, Paine M, O'Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol 2005;25:14-17.
25. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
26. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309- 18.
27. Wilke WS. Large vessel vasculitis (giant cell arteritis, Takayasu arteritis). Baillieres Clin Rheumatol 1997;11:285-313.
28. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504.
29. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-17.
30. Staunton H, Stafford F, Leader M, et al. Deterioration of giant cell arteritis with corticosteroid therapy. Arch Neurol 2000;57:581-4.
31. Rauzy O, Fort M, Nourashemi F, et al. Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998;57:380-2.
32. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332-7.
33. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis syndrome with adrenal corticosteroids. JAMA 1957;163:821-7.
34. Palm E. The ocular crisis of the temporal arteritis syndrome (Horton). Acta Ophthalmol 1958;36:208-43.
35. Parson-Smith G. Sudden blindness in cranial arteritis. Br J Ophthalmol 1959;43:204-16.
36. Russell RWR. Giant cell arteritis. A review of 35 cases. Q J Med 1959;112:471-89.
37. Whitfield AGW, Bateman M, Cooke WT. Temporal arteritis. Br J Ophthalmol 1963;47:555-66.
38. Cullen JF. Ischaemic optic neuropathy. Trans Ophthal Soc UK 1967;87:759-74.
39. Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica. Ann Intern Med 1972;77:845-52.
40. Hunder GG, Sheps SG, Allen LA, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis. Ann Intern Med 1975;82:613-18.
41. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981;24:899-904.
42. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40:1-5.
43. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. Arthritis Rheum 1987;30:295-9.
44. Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988;38:352-9.
45. Kyle V, Hazleman BL. Treatment of polymyalgia and giant cell arteritis. I. Steroid regimens for the first two months. Ann Rheum Dis 1989;48:658-61.
46. Myles AB, Perera T, Ridley MG. Treatment of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992;31:103-5.
47. Aiello PD, Trautmann JC, McPhee JT, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
48. Duhaut P, Pinede L, Bornet H, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Arterite a Cellules Geantes. Ann Rheum Dis 1999;58:335-41.
49. Kupersmith MJ, Langer R, Mitnick H, et al. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy. Br J Ophthalmol 1999;83:796-801.
50. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.